Baker McKenzie advised Minoryx Therapeutics on the deal. Clifford Chance advised the Neuraxpharm Group. Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here